PMID- 24091827
OWN - NLM
STAT- MEDLINE
DCOM- 20141121
LR  - 20211021
IS  - 1559-1182 (Electronic)
IS  - 0893-7648 (Linking)
VI  - 49
IP  - 2
DP  - 2014 Apr
TI  - An evaluation of the effects of acute and chronic L-tyrosine administration on 
      BDNF levels and BDNF mRNA expression in the rat brain.
PG  - 734-40
LID - 10.1007/s12035-013-8552-1 [doi]
AB  - Tyrosinemia type II, which is also known as Richner-Hanhart syndrome, is an 
      inborn error of metabolism that is due to a block in the transamination reaction 
      that converts tyrosine to p-hydroxyphenylpyruvate. Because the mechanisms of 
      neurological dysfunction in hypertyrosinemic patients are poorly known and the 
      symptoms of these patients are related to the central nervous system, the present 
      study evaluated brain-derived neurotrophic factor (BDNF) levels and bdnf mRNA 
      expression in young rats and during growth. In our acute protocol, Wistar rats 
      (10 and 30 days old) were killed 1 h after a single intraperitoneal L-tyrosine 
      injection (500 mg/kg) or saline. Chronic administration consisted of L-tyrosine 
      (500 mg/kg) or saline injections 12 h apart for 24 days in Wistar rats (7 days 
      old), and the rats were killed 12 h after the last injection. The brains were 
      rapidly removed, and we evaluated the BDNF levels and bdnf mRNA expression. The 
      present results showed that the acute administration of L-tyrosine decreased both 
      BDNF and bdnf mRNA levels in the striatum of 10-day-old rats. In the 30-day-old 
      rats, we observed decreased BDNF levels without modifications in bdnf transcript 
      level in the hippocampus and striatum. Chronic administration of L-tyrosine 
      increased the BDNF levels in the striatum of rats during their growth, whereas 
      bdnf mRNA expression was not altered. We hypothesize that oxidative stress can 
      interact with the BDNF system to modulate synaptic plasticity and cognitive 
      function. The present results enhance our knowledge of the pathophysiology of 
      hypertyrosinemia.
FAU - Ferreira, Gabriela K
AU  - Ferreira GK
AD  - Laboratorio de Bioenergetica, Programa de Pos-graduacao em Ciencias da Saude, 
      Universidade do Extremo Sul Catarinense, Av. Universitaria, 1105, Criciuma, 
      88806-000, Santa Catarina, Brazil.
FAU - Scaini, Giselli
AU  - Scaini G
FAU - Jeremias, Isabela C
AU  - Jeremias IC
FAU - Carvalho-Silva, Milena
AU  - Carvalho-Silva M
FAU - Goncalves, Cinara L
AU  - Goncalves CL
FAU - Pereira, Talita C B
AU  - Pereira TC
FAU - Oliveira, Giovanna M T
AU  - Oliveira GM
FAU - Kist, Luiza W
AU  - Kist LW
FAU - Bogo, Mauricio R
AU  - Bogo MR
FAU - Schuck, Patricia F
AU  - Schuck PF
FAU - Ferreira, Gustavo C
AU  - Ferreira GC
FAU - Streck, Emilio L
AU  - Streck EL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131004
PL  - United States
TA  - Mol Neurobiol
JT  - Molecular neurobiology
JID - 8900963
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - 42HK56048U (Tyrosine)
SB  - IM
MH  - Animals
MH  - Brain/drug effects/*metabolism
MH  - Brain-Derived Neurotrophic Factor/*biosynthesis
MH  - Drug Evaluation, Preclinical/methods
MH  - *Gene Expression Regulation
MH  - Male
MH  - Oxidative Stress/drug effects/physiology
MH  - RNA, Messenger/*biosynthesis
MH  - Rats
MH  - Rats, Wistar
MH  - Tyrosine/*administration & dosage
EDAT- 2013/10/05 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/10/05 06:00
PHST- 2013/06/20 00:00 [received]
PHST- 2013/08/29 00:00 [accepted]
PHST- 2013/10/05 06:00 [entrez]
PHST- 2013/10/05 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1007/s12035-013-8552-1 [doi]
PST - ppublish
SO  - Mol Neurobiol. 2014 Apr;49(2):734-40. doi: 10.1007/s12035-013-8552-1. Epub 2013 
      Oct 4.